BR0008317A - Processo para diagnosticar e distinguir acidente vascular cerebral - Google Patents

Processo para diagnosticar e distinguir acidente vascular cerebral

Info

Publication number
BR0008317A
BR0008317A BR0008317-8A BR0008317A BR0008317A BR 0008317 A BR0008317 A BR 0008317A BR 0008317 A BR0008317 A BR 0008317A BR 0008317 A BR0008317 A BR 0008317A
Authority
BR
Brazil
Prior art keywords
stroke
subject
type
protein
diagnose
Prior art date
Application number
BR0008317-8A
Other languages
English (en)
Inventor
George Jackowski
Original Assignee
Syn X Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn X Pharma filed Critical Syn X Pharma
Publication of BR0008317A publication Critical patent/BR0008317A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001—Enzyme electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/969—Multiple layering of reactants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/97—Test strip or test slide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/81—Tube, bottle, or dipstick
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Length Measuring Devices Characterised By Use Of Acoustic Means (AREA)
  • Eye Examination Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

"PROCESSO PARA DIAGNOSTICAR E DISTINGUIR ACIDENTE VASCULAR CEREBRAL". Processo para a determinação de se um indivíduo teve um acidente vascular cerebral e, em caso afirmativo, do tipo de acidente vascular cerebral, que inclui a análise do fluido corporal do indivíduo quanto a pelo menos quatro marcadores selecionados de acidente vascular cerebral, a saber, proteína básica de mielina, proteína S100, enolase específica neuronal e uma proteína de membrana endotelial cerebral, como trombomodulina ou uma molécula similar. Os dados obtidos das análises fornecem informações quanto ao tipo de acidente vascular cerebral, ao início da ocorrência e a extensão da lesão cerebral, e permitem que um médico determine rapidamente o tipo de tratamento requerido pelo indivíduo.
BR0008317-8A 1999-02-26 2000-02-22 Processo para diagnosticar e distinguir acidente vascular cerebral BR0008317A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002263063A CA2263063C (en) 1999-02-26 1999-02-26 Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
PCT/CA2000/000182 WO2000052476A1 (en) 1999-02-26 2000-02-22 Method for diagnosing and distinguishing stroke

Publications (1)

Publication Number Publication Date
BR0008317A true BR0008317A (pt) 2002-01-29

Family

ID=4163334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008317-8A BR0008317A (pt) 1999-02-26 2000-02-22 Processo para diagnosticar e distinguir acidente vascular cerebral

Country Status (14)

Country Link
US (1) US6235489B1 (pt)
EP (2) EP1521083A3 (pt)
JP (1) JP4560212B2 (pt)
CN (1) CN1339108A (pt)
AT (1) ATE283485T1 (pt)
AU (1) AU765923B2 (pt)
BR (1) BR0008317A (pt)
CA (1) CA2263063C (pt)
DE (1) DE60016178T2 (pt)
DK (1) DK1155325T3 (pt)
ES (1) ES2232424T3 (pt)
NZ (1) NZ513005A (pt)
PT (1) PT1155325E (pt)
WO (1) WO2000052476A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19837387A1 (de) * 1998-08-18 2000-02-24 Aventis Res & Tech Gmbh & Co 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung
US7297544B2 (en) * 1998-10-02 2007-11-20 Ischemia Technologies, Inc. Tests for the rapid evaluation of ischemic states and kits
US7070937B1 (en) 1998-10-02 2006-07-04 Ischemia Technologies, Inc. Marker useful for detection and measurement of free radical damage and method
US7449338B2 (en) 1998-10-02 2008-11-11 Ischemia Technologies, Inc. Tests for the rapid evaluation of ischemic states and kits
US20030215359A1 (en) * 1998-10-02 2003-11-20 Ischemia Technologies, Inc. Tests for the rapid evaluation of ischemic states and kits
US6475743B1 (en) 1998-10-02 2002-11-05 Ischemia Technologies, Inc. Marker useful for detection and measurement of free radical damage and method
US20050142613A1 (en) * 1998-10-02 2005-06-30 David Bar-Or Test for the rapid evaluation of ischemic states and kits
US6780606B1 (en) * 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US20070026440A1 (en) * 2001-04-06 2007-02-01 Broderick Patricia A Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using electrodes with microvoltammetry
EP1385421A4 (en) * 2001-04-06 2007-01-24 Univ City IDENTIFICATION, DIAGNOSIS AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS AND CEREBRAL AND MEDULLAION LESIONS BY MICROVOLTAMETRY USING MICRO ELECTRODES
US7524635B2 (en) 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040176914A1 (en) * 2001-04-13 2004-09-09 Biosite Incorporated Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US7427490B2 (en) 2001-08-20 2008-09-23 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US20020160420A1 (en) * 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
ATE349181T1 (de) * 2001-05-04 2007-01-15 Ischemia Tech Inc Verbesserungen der diagnose des akuten myokardinfarkts und anderer klinischer zustände
JP4268347B2 (ja) * 2001-05-30 2009-05-27 富士フイルム株式会社 乾式分析素子用の管理血清
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20030040660A1 (en) * 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
AU2002336845A1 (en) * 2001-11-23 2003-06-10 Syn.X Pharma, Inc. Globin biopolymer markers indicative of insulin resistance
GB0203768D0 (en) * 2002-02-18 2002-04-03 Univ Geneve Diagnostic method for stroke
US20050153360A1 (en) * 2002-02-18 2005-07-14 Hochstrasser Denis F. Diagnostic method for stroke
SE0200860D0 (sv) * 2002-03-20 2002-03-20 Monica Almqvist Microfluidic cell and method for sample handling
US7115103B2 (en) * 2002-08-31 2006-10-03 Peter Trexler Keith Stroke symptom recognition devices and methods
EP1867734A1 (en) * 2002-12-24 2007-12-19 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
EP1587955A4 (en) * 2002-12-24 2007-03-14 Biosite Inc DIFFERENTIAL DIAGNOSTIC MARKERS AND METHODS OF USE
JP2006521562A (ja) 2003-03-07 2006-09-21 スレショルド ファーマシューティカルズ インコーポレイティッド 抗悪性腫瘍剤による治療に対する腫瘍の感受性を決定する方法
GB2404981A (en) * 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
CN100373820C (zh) * 2003-10-08 2008-03-05 松下电器产业株式会社 道路-车辆通信系统以及用于其中的路边设备和移动设备
AP2787A (en) * 2005-06-21 2013-10-31 Us Gov Health & Human Serv Methods, immunoassays and devices for detection ofanti-lipoidal antibodies
US8148057B2 (en) 2005-06-21 2012-04-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Methods, immunoassays and devices for detection of anti-lipoidal antibodies
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
DE102007004991B4 (de) 2006-08-14 2018-08-30 Varicula Biotec GmbH Verwendung von RiV-Präparaten zur Behandlung des Hirninfarktes
DE102007026910A1 (de) 2007-06-12 2008-12-18 Siemens Ag Untersuchungseinheit mit integrierter Minilabor-Analyseeinheit
US9159127B2 (en) 2007-06-20 2015-10-13 Koninklijke Philips N.V. Detecting haemorrhagic stroke in CT image data
DE102007042986A1 (de) 2007-09-10 2009-04-23 Siemens Ag Medizinisches Gerät und Verfahren zum Betreiben eines medizinischen Geräts
RU2491291C2 (ru) * 2009-02-16 2013-08-27 Общество С Ограниченной Ответственностью "Герофарм" Модифицированный пептид и его использование для тестирования онкологических заболеваний цнс и эффективности терапии
US20100228101A1 (en) * 2009-03-04 2010-09-09 Michael Maschke Workflow for stroke diagnosis combining in-vitro diagnosis (ivd) with an imaging modality
US20100331833A1 (en) * 2009-06-26 2010-12-30 Michael Maschke In-vitro device monitoring during minimally invasive ablation therapy
US20100332254A1 (en) * 2009-06-26 2010-12-30 Michael Maschke In-vitro device support for x-ray based kidney function test
US20100331673A1 (en) * 2009-06-26 2010-12-30 Michael Maschke System and method for reducing patient risk of allergic reaction to contrast agents or medical material
GB201008541D0 (en) * 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
WO2012137832A1 (ja) 2011-04-05 2012-10-11 オリンパス株式会社 膵臓検査方法および膵臓検査キット
JP6392202B2 (ja) 2012-03-13 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティ 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質
EP3250926B1 (en) * 2015-01-30 2019-10-16 Cyrex Laboratories, LLC Simultaneous characterization of igg and iga antibodies to multiple food antigens and c1q-food protein immune complexes
CN107533048A (zh) 2015-02-05 2018-01-02 美国免疫阵列公司 用于诊断脑损伤或神经退行性变的方法和组合物
CN110366558A (zh) 2016-10-28 2019-10-22 班扬生物标记公司 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
CN113970640B (zh) * 2020-07-24 2022-07-08 首都医科大学附属北京天坛医院 用于ich预后评估的生物标记物及其应用
CN117054669B (zh) * 2023-10-11 2024-03-29 北京美联泰科生物技术有限公司 急性缺血性脑卒中的诊断或预测标志物、产品和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2825283B2 (ja) * 1989-08-21 1998-11-18 日本臓器製薬株式会社 血管障害判定法
JPH0736019B2 (ja) * 1989-12-27 1995-04-19 富士薬品工業株式会社 新規な抗ヒトトロンボモジュリンモノクローナル抗体によるヒトトロンボモジュリンおよびその分解産物の定量方法
JP3057093B2 (ja) * 1990-09-30 2000-06-26 日本臓器製薬株式会社 細胞傷害防御能測定法
CA2027434C (en) * 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5710008B1 (en) * 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
RU1802337C (ru) * 1990-12-21 1993-03-15 Центральный Военный Клинический Госпиталь Им.А.А.Вишневского Способ определени объема мозгового инфаркта при ишемическом инсульте
JPH05219982A (ja) * 1992-02-07 1993-08-31 Toshiba Corp 脳に分布する蛋白質に対するモノクローナル抗体
JP3073667B2 (ja) * 1995-06-01 2000-08-07 オリエンタル酵母工業株式会社 脳卒中の新規マーカー
JPH09322783A (ja) * 1996-04-05 1997-12-16 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ
SE9602677D0 (sv) 1996-07-05 1996-07-05 Sangtec Medical Ab Methods for determining brain antigens
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7427490B2 (en) * 2001-08-20 2008-09-23 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof

Also Published As

Publication number Publication date
US6235489B1 (en) 2001-05-22
CA2263063A1 (en) 2000-08-26
ATE283485T1 (de) 2004-12-15
DK1155325T3 (da) 2005-04-04
EP1521083A2 (en) 2005-04-06
EP1155325A1 (en) 2001-11-21
DE60016178T2 (de) 2005-12-01
AU765923B2 (en) 2003-10-02
WO2000052476A1 (en) 2000-09-08
AU2788400A (en) 2000-09-21
JP2002538463A (ja) 2002-11-12
ES2232424T3 (es) 2005-06-01
CN1339108A (zh) 2002-03-06
PT1155325E (pt) 2005-03-31
DE60016178D1 (de) 2004-12-30
JP4560212B2 (ja) 2010-10-13
EP1521083A3 (en) 2008-06-25
EP1155325B1 (en) 2004-11-24
CA2263063C (en) 2004-08-10
NZ513005A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
BR0008317A (pt) Processo para diagnosticar e distinguir acidente vascular cerebral
Hyman et al. Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
AU2003269772A1 (en) Method and arrangement for interpreting a subjects head and eye activity
DE60042695D1 (de) Verfahren für den nachweis von erkrankungen
BR0209262A (pt) Processo para diagnóstico diferencial de demência de alzheimer e kit para o mesmo
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
ATE539069T1 (de) Isotopenmarkierte benzofuranverbindungen als bilddarstellende mittel für amyloidogene proteine
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
EP1532438A4 (en) OLIGOSACCHARIDE BIOMARKERS FOR MUCOPOLYSACCHARIDOSES AND OTHER RELATED DISORDER
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
EP1179588A4 (en) HUMAN BRAIN-SPECIFIC CARBOXYPEPTIDASE
FR2765591B1 (fr) Procede de diagnostic de la maladie d'alzheimer
DE60216570D1 (de) Verfahren zum nachweis von alzheimer-krankheit
WO2003016497A3 (en) Molecules for disease detection and treatment
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2001038581A3 (en) Vigilance nucleic acids and related diagnostic, screening and therapeutic methods
DE60127161D1 (de) Verbesserte diagnose von psychiatrischen störungen anhand von herzschlagdaten
WO2003038052A3 (en) Nucleic acid-associated proteins
PT1292187E (pt) Modelo animal transgenico de disturbios neurodegenerativos
ATE312914T1 (de) Rdgb-proteine
WO2004098391A3 (en) Methods for detecting parvovirous infections
WO2003031595A3 (en) Molecules for disease detection and treatment
WO2005001483A3 (en) Methods for diagnisis and differential diagnosis of dementia disorders
WO2003046152A3 (en) Molecules for disease detection and treatment

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SYN X PHARMA (CA)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME SOLICITADO NA PETICAO NO 046993/RJ DE 22/08/2003.

B25D Requested change of name of applicant approved

Owner name: NANOGEN POINT OF CARE, INC. (CA)

Free format text: ALTERADO DE: SYNX PHARMA INC.

B25A Requested transfer of rights approved

Owner name: NANOGEN, INC. (US)

Free format text: TRANSFERIDO DE: NANOGEN POINT OF CARE, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 10 (VIII), 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.